title: Adjunctive medical therapies for acute stroke thrombolysis: is there a CLEAR-ER choice?
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Barreto
authors.forename: Claudia
authors.initials: C
authors.lastname: Pedroza
authors.forename: James C
authors.initials: JC
authors.lastname: Grotta
mesh_terms: D002545:Brain Ischemia / Q000188:drug therapy*; D000077542:Eptifibatide; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects*; D006801:Humans; D020300:Intracranial Hemorrhages / Q000139:chemically induced*; D008297:Male; D010455:Peptides / Q000009:adverse effects*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D020521:Stroke / Q000188:drug therapy*; D015912:Thrombolytic Therapy / Q000009:adverse effects*; D010959:Tissue Plasminogen Activator / Q000009:adverse effects*
chemical_list: D005343:Fibrinolytic Agents; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D010959:Tissue Plasminogen Activator; D000077542:Eptifibatide
keywords: Bayes theorem; platelet glycoprotein GPIIb-IIIa complex; stroke; thrombolytic therapy